ASCIMINIB HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for asciminib hydrochloride and what is the scope of patent protection?
Asciminib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Asciminib hydrochloride has eighty-four patent family members in forty-nine countries.
One supplier is listed for this compound.
Summary for ASCIMINIB HYDROCHLORIDE
International Patents: | 84 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 16 |
Patent Applications: | 2 |
DailyMed Link: | ASCIMINIB HYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ASCIMINIB HYDROCHLORIDE
Generic Entry Date for ASCIMINIB HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ASCIMINIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Novartis | Phase 3 |
Sarit Assouline | Phase 3 |
Augusta University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for ASCIMINIB HYDROCHLORIDE
US Patents and Regulatory Information for ASCIMINIB HYDROCHLORIDE
International Patents for ASCIMINIB HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Jordan | 3453 | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 (Benzamide Derivatives FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1) | ⤷ Sign Up |
South Africa | 201407065 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ⤷ Sign Up |
Japan | 2022532404 | N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3R)-3-ヒドロキシピロリジン-1-イル]-5-(1H-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態 | ⤷ Sign Up |
Mexico | 359014 | DERIVADOS DE BENZAMIDA PARA LA INHIBICION DE LA ACTIVIDAD DE ABL1, ABL2 Y BCR-ABL1. (BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1.) | ⤷ Sign Up |
Peru | 20161416 | DERIVADOS DE BENZAMIDA PARA LA INHIBICION DE LA ACTIVIDAD ABL1, ABL2 Y BCR-ABL1 | ⤷ Sign Up |
Guatemala | 201400253 | DERIVADOS DE BENZAMIDA PARA LA INHIBICIÓN DE LA ACTIVIDAD DE ABL1, ABL2 Y BCR-ABL1 | ⤷ Sign Up |
South Korea | 20220009414 | N-[4-페닐]-6-[(3R)-3-히드록시피롤리딘-1-일]-5-(1H-피라졸-5-일)피리딘-3-카복사미드의 결정질 형태 | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ASCIMINIB HYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2861579 | C202230056 | Spain | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, TAL COMO HIDROCLORURO DE ASCIMINIB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF AUTHORISATION: 20220825; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1670; DATE OF FIRST AUTHORISATION IN EEA: 20220825 |
2861579 | 2290039-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1670 20220826 |
2861579 | 22C1053 | France | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TEL QUE LE CHLORHYDRATE D'ASCIMINIB; REGISTRATION NO/DATE: EU/1/22/1670 20220826 |
2861579 | 2022C/548 | Belgium | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ZOALS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826 |
2861579 | C20220039 00385 | Estonia | ⤷ Sign Up | PRODUCT NAME: ASTSIMINIIB;REG NO/DATE: EU/1/22/1670 26.08.2022 |
2861579 | 122022000072 | Germany | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, WIE ZUM BEISPIEL ASCIMINIBHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1670 20220825 |
2861579 | CR 2022 00046 | Denmark | ⤷ Sign Up | PRODUCT NAME: ASCIMINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SASOM ASCIMINIB HYDROKLORID; REG. NO/DATE: EU/1/22/1670 20220826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |